BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sirpiglenastat readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sirpiglenastat\, from ClinicalTrials.gov 
 estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07249372-2111@assetmemo.bio
DTSTAMP:20261121T005734Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Sirpiglenastat: Phase 2 readout est. (NCT07249372)
DESCRIPTION:Sirpiglenastat\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: 
 DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer\n
 Estimated primary completion: 31 October 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/sirpiglenastat#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07249372
URL:https://assetmemo.bio/drug/sirpiglenastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06027086-2111@assetmemo.bio
DTSTAMP:20261121T005734Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Sirpiglenastat: Phase 1/2 readout est. (NCT06027086)
DESCRIPTION:Sirpiglenastat\, phase 1/2.\nStudy: DRP-104 (Glutamine Antagoni
 st) in Combination With Durvalumab in Patients With Advanced Stage Fibrola
 mellar Carcinoma (FLC)\nEstimated primary completion: 1 September 2028. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/sirpiglenastat#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06027086
URL:https://assetmemo.bio/drug/sirpiglenastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07430202-2111@assetmemo.bio
DTSTAMP:20261121T005734Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Sirpiglenastat: Phase 1 readout est. (NCT07430202)
DESCRIPTION:Sirpiglenastat\, phase 1.\nStudy: A DNAJB1-PRKACA Fusion Kinase
  Peptide Vaccine Combined With Glutamine Antagonist DRP-104\, Nivolumab\, 
 and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FL
 C)\nEstimated primary completion: October 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/sirpiglenastat#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07430202
URL:https://assetmemo.bio/drug/sirpiglenastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
